


Metastatic Colorectal Cancer Treatment Options



*Cetuximab and panitumumab are only for patients with RAS wild-type tumors.

**Bevacizumab is the preferred anti-angiogenic agent based on toxicity and/or cost.

ccalliance.org | Helpline: (877) 422-2030

The Colorectal Cancer Alliance is a national organization committed to ending colorectal cancer within our lifetime. We are your allies — a national network of passionate survivors, caregivers and advocates dedicated to helping you and your family navigate all aspects of the disease, from diagnosis and treatment to a lifetime of progression-free survival. We are a community of people eager to share experiences, address your concerns, and answer your questions. We understand the different stages of the colorectal cancer journey because we've been there. We are here for you when you need us because we believe tomorrow can't wait.



Metastatic Colorectal Cancer Treatment Options

Generic Name	Trade Name	Abbreviated As
cetuximab	Erbitux*	cet
capecitabine	Xeloda	XEL, CAPE or CAP
panitumumab	Vectibix*	pan
oxaliplatin	Eloxatin	OX
bevacizumab	Avastin	bev
fluorouracil + leucovorin	–	5-FU or FOLF
irinotecan	Camptosar	IRI
regorafenib	Stivarga	–
ziv-aflibercept	Zaltrap	–
ramucirumab	Cyramza	–
trifluridine + tipiracil	Lonsurf	TAS-102

Abbreviated As	Treatment
FOLFOX	5FU+oxaliplatin
FOLFIRI	5FU+irinotecan
FOLFOXIRI	5FU+oxaliplatin+irinotecan
CAPEOX	capecitabine+oxaliplatin

To view the most recent and complete version of this guideline, go online to [NCCN.org](https://www.NCCN.org).

This chart is adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and contains some examples of possible treatment pathways for metastatic colorectal cancer. Use it to discuss your options with your doctor. You should always see what clinical trials are available at every line of treatment. Always talk to your doctor about available clinical trials and tumor gene testing before beginning treatment.

*Cetuximab and panitumumab are only for patients with RAS wild-type tumors.

**Bevacizumab is the preferred anti-angiogenic agent based on toxicity and/or cost.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer Version 2.2021. © National Comprehensive Cancer Network, Inc 2021. All rights reserved. Accessed [May 2021]. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.NCCN.org). NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

The Colorectal Cancer Alliance, Inc. is a not-for-profit 501(c)3 corporation. Tax ID# 86-0947831.